Myriad Genetics (MYGN) announces Mark Capone has resigned as President and CEO
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Myriad Genetics (MYGN) PT Lowered to $19 at Jefferies
February 7, 2020 9:14 AM ESTJefferies analyst Brandon Couillard lowered the price target on Myriad Genetics (NASDAQ: MYGN) to $19.00 (from $23.00) while maintaining a Hold rating.
The analyst commented, "We expect MYGN to open sharply lower (down >20% after-hours) after another 2Q miss, ~50% cut to '20 EPS guide & abrupt CEO... More
Myriad Genetics (MYGN) Misses Q2 EPS by 8c, Guidance Misses
February 6, 2020 4:13 PM ESTMyriad Genetics (NASDAQ: MYGN) reported Q2 EPS of $0.23, $0.08 worse than the analyst estimate of $0.31. Revenue for the quarter came in at $195.1 million versus the consensus estimate of $209.81 million.
GUIDANCE:
Myriad Genetics sees Q3 2020 EPS of $0.02, versus the consensus of $0.30. Myriad... More
